TY - JOUR
T1 - Kinetics and 28-day test–retest repeatability and reproducibility of [11C]UCB-J PET brain imaging
AU - Tuncel, Hayel
AU - Boellaard, Ronald
AU - Coomans, Emma M.
AU - de Vries, Erik F. J.
AU - Glaudemans, Andor W. JM
AU - Feltes, Paula Kopschina
AU - García, David V.
AU - Verfaillie, Sander C. J.
AU - Wolters, Emma E.
AU - Sweeney, Steven P.
AU - Ryan, J. Michael
AU - Ivarsson, Magnus
AU - Lynch, Berkley A.
AU - Schober, Patrick
AU - Scheltens, Philip
AU - Schuit, Robert C.
AU - Windhorst, Albert D.
AU - de Deyn, Peter P.
AU - van Berckel, Bart N. M.
AU - Golla, Sandeep S. V.
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was made possible by Rodin Therapeutics Inc. by providing funding for the study.
Publisher Copyright:
© The Author(s) 2020.
PY - 2021/6/1
Y1 - 2021/6/1
N2 - [11C]UCB-J is a novel radioligand that binds to synaptic vesicle glycoprotein 2A (SV2A). The main objective of this study was to determine the 28-day test–retest repeatability (TRT) of quantitative [11C]UCB-J brain positron emission tomography (PET) imaging in Alzheimer’s disease (AD) patients and healthy controls (HCs). Nine HCs and eight AD patients underwent two 60 min dynamic [11C]UCB-J PET scans with arterial sampling with an interval of 28 days. The optimal tracer kinetic model was assessed using the Akaike criteria (AIC). Micro-/macro-parameters such as tracer delivery (K1) and volume of distribution (VT) were estimated using the optimal model. Data were also analysed for simplified reference tissue model (SRTM) with centrum semi-ovale (white matter) as reference region. Based on AIC, both 1T2k_VB and 2T4k_VB described the [11C]UCB-J kinetics equally well. Analysis showed that whole-brain grey matter TRT for VT, DVR and SRTM BPND were –2.2% ± 8.5, 0.4% ± 12.0 and –8.0% ± 10.2, averaged over all subjects. [11C]UCB-J kinetics can be well described by a 1T2k_VB model, and a 60 min scan duration was sufficient to obtain reliable estimates for both plasma input and reference tissue models. TRT for VT, DVR and BPND was <15% (1SD) averaged over all subjects and indicates adequate quantitative repeatability of [11C]UCB-J PET.
AB - [11C]UCB-J is a novel radioligand that binds to synaptic vesicle glycoprotein 2A (SV2A). The main objective of this study was to determine the 28-day test–retest repeatability (TRT) of quantitative [11C]UCB-J brain positron emission tomography (PET) imaging in Alzheimer’s disease (AD) patients and healthy controls (HCs). Nine HCs and eight AD patients underwent two 60 min dynamic [11C]UCB-J PET scans with arterial sampling with an interval of 28 days. The optimal tracer kinetic model was assessed using the Akaike criteria (AIC). Micro-/macro-parameters such as tracer delivery (K1) and volume of distribution (VT) were estimated using the optimal model. Data were also analysed for simplified reference tissue model (SRTM) with centrum semi-ovale (white matter) as reference region. Based on AIC, both 1T2k_VB and 2T4k_VB described the [11C]UCB-J kinetics equally well. Analysis showed that whole-brain grey matter TRT for VT, DVR and SRTM BPND were –2.2% ± 8.5, 0.4% ± 12.0 and –8.0% ± 10.2, averaged over all subjects. [11C]UCB-J kinetics can be well described by a 1T2k_VB model, and a 60 min scan duration was sufficient to obtain reliable estimates for both plasma input and reference tissue models. TRT for VT, DVR and BPND was <15% (1SD) averaged over all subjects and indicates adequate quantitative repeatability of [11C]UCB-J PET.
KW - Aged
KW - Aged, 80 and over
KW - Alzheimer Disease/diagnostic imaging
KW - Female
KW - Humans
KW - Image Interpretation, Computer-Assisted
KW - Kinetics
KW - Male
KW - Membrane Glycoproteins/metabolism
KW - Middle Aged
KW - Nerve Tissue Proteins/metabolism
KW - Neuroimaging/methods
KW - Positron-Emission Tomography/methods
KW - Pyridines/pharmacokinetics
KW - Pyrrolidinones/pharmacokinetics
KW - Radiopharmaceuticals/pharmacokinetics
KW - Reproducibility of Results
UR - https://www.scopus.com/pages/publications/85092298429
UR - https://www.ncbi.nlm.nih.gov/pubmed/34013797
UR - https://www.scopus.com/pages/publications/85092298429
U2 - 10.1177/0271678X20964248
DO - 10.1177/0271678X20964248
M3 - Article
C2 - 34013797
SN - 0271-678X
VL - 41
SP - 1338
EP - 1350
JO - Journal of cerebral blood flow and metabolism
JF - Journal of cerebral blood flow and metabolism
IS - 6
ER -